PRODUCT INFORMATION

HS-1371

Item No. 31033

CAS Registry No.:	2158197-70-5
Formal Name:	4-(4-methylphenoxy)-7-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-quinoline
MF:	$C_{24}H_{24}N_4O$
FW:	384.5
Purity:	≥98%
UV/Vis.:	λ_{max}: 267 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

HS-1371 is supplied as a solid. A stock solution may be made by dissolving the HS-1371 in the solvent of choice, which should be purged with an inert gas. HS-1371 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of HS-1371 in DMF is approximately 30 mg/ml and approximately 5 mg/ml in ethanol and DMSO.

HS-1371 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, HS-1371 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. HS-1371 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

HS-1371 is a receptor-interacting serine/threonine kinase 3 (RIPK3) inhibitor (IC_{50} = 20.8 nM).[1] It inhibits basal RIPK3 autophosphorylation and TNF-α- or TRAIL-induced necroptosis in HT-29 cells when used at a concentration of 5 µM. It also inhibits necroptosis induced by a TNF-α Smac mimetic and the caspase inhibitor Z-VAD in HeLa cervical and NCI-H2009 lung cancer cells ectopically expressing RIPK3.

Reference

1. Park, H.-H., Park, S.-Y., Mah, S., *et al*. HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosis. *Exp. Mol. Med.* **50(9)**, 1-15 (2018).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM